Utrogestan

PreclinicalSmall molecule

UUniversity of Athens

Utrogestan is one of 29 small molecule programs targeting Growth. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GrowthActive, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Lovenox

Sanofi

Preclinical

2 3

Aricept

Eisai

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 6

Lenvima

Eisai

Preclinical

1 7

Herceptin

OOrganon and Co

Preclinical

4 8

Glucophage

EMD Serono

Preclinical

2 9

EGRIFTA WR

TTheratechnologies

Preclinical

2 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Pregnancy

NCT06870266

Clinical

Trials by Indication[1]

Progesterone3 trials

Vaginal Versus Combined Use of Progesterone in Fresh IVF/ICSI Cycles

Unknown status·UUniversity of Athens··NCT05089383·698 enrolled

Progesterone and Resting Energy Expenditure

Terminated·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT04140968·2 enrolled

Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders

Unknown status·—·Phase 4·NCT04797338·100 enrolled

Randomised Controlled Trial1 trial

Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial

Unknown status·Nnor zila hassan malek·Phase 2·NCT01985594·32 enrolled

Growth1 trial

Endometrial Heparin-binding Epidermal Growth Factor Expression

Unknown status·NNational University of Malaysia··NCT04175002·40 enrolled

Pregnancy1 trial

Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone

Not yet recruiting·SShaare Zedek Medical Center·Phase 1·NCT06870266·150 enrolled

Elective1 trial

Implantation Enhancement by Elective Cryopreservation of All Viable Embryos

Completed·UUniversitair Ziekenhuis Brussel·N/A·NCT02148393·212 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Utrogestan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Utrogestan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Utrogestan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Athens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Athens

Utrogestan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Progesterone3 trials

Randomised Controlled Trial1 trial

Growth1 trial

Pregnancy1 trial

Elective1 trial

References

Drug Info

Quick Facts

Related News